The evolving role of cardiac troponin in the evaluation of cardiac disorders topical collection on ischemic heart disease

Current Cardiology Reports

Volumn 15, Issue 11, 2013, Pages

  Anaya, Paul ^a   Moliterno, David J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Acute coronary syndrome; Acute myocardial infarction; Biomarker; Cardiac disorders; Cardiac troponin; Cardiotoxicity; Evaluation; High sensitivity; Myocardial necrosis

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CREATINE KINASE MB; FIBRINOLYTIC AGENT; TROPONIN; TROPONIN I;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; CORONARY ARTERY BYPASS SURGERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG MEGADOSE; EUROSCORE; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE NECROSIS; HUMAN; LUNG EMBOLISM; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); MORTALITY; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SURGICAL THROMBECTOMY; SURVIVAL RATE; TISSUE SPECIFICITY; TREATMENT OUTCOME; BLOOD; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; EARLY DIAGNOSIS; METABOLISM; MYOCARDIAL INFARCTION; NECROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PULMONARY EMBOLISM; SENSITIVITY AND SPECIFICITY;

BIOMARKERS; EARLY DIAGNOSIS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; NECROSIS; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY EMBOLISM; SENSITIVITY AND SPECIFICITY; TROPONIN;

EID: 84886909416     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-013-0420-0     Document Type: Article

References (63)

1. • Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation. 2012;126:2020-35. Updated recommendations on the appropriate use of cardiac biomarkers in the evaluation of patients with suspected AMI.
2. Bandman E. Contractile protein isoforms in muscle development. Dev Biol. 1992;154:273-83.
3. US National Library of Medicine. Genetics Home Reference. Available at: http://ghr.nlm.nih.gov/gene. Accessed March 2012.
4. Jaffe AS, Vasile VC, Milone M, et al. Diseased skeletal muscle: a non cardiac source of increased circulating concentrations of cardiac troponin T. JACC. 2011;58:1819-24.
5. Katus HA. Development of the cardiac troponin T immunoassay. Clin Chem. 2008;54:1576-7.
6. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58:54-61.
7. Apple FS, Jesse RL, Newby K, Wu AHB, Christenson RH. National academy of clinical biochemistry and IFCC committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: analytical issues for biochemical markers of acute coronary syndromes. Clin Chem. 2007;53:547-51. (Pubitemid 46580222)
8. Kavsak PA, MacRae AR, Yerna M-J, Jaffe AS. Analytic and clinical utility of a next-generation, highly sensitive cardiac troponin I assay for early detection of myocardial injury. Clin Chem. 2009;55:573-7.
9. Apple FS. A new season for cardiac troponin assays: it's time to keep a scorecard. Clin Chem. 2009;55:1303-6.
10. Scharnhorst V, Krasznai K, van't Veer M, Michels RH. Variation of cardiac troponin I and T measured with sensitive assays in emergency department patients with noncardiac chest pain. Clin Chem. 2012;58:1208-14.
11. Cardinaels EPM, Mingels AMA, Jacobs LHJ, et al. A comprehensive review of upper reference limits reported for (high-)sensitivity cardiac troponin assays: the challenges that lie ahead. Clin Chem Lab Med. 2012;50:791-806.
12. Normann J, Mueller M, Biener M, et al. Effect of older age on diagnostic and prognostic performance of high sensitivity troponin T in patients presenting to an emergency department. Am Heart J. 2012;164:698-705.
13. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Circulation. 2007;116:2634-53. (Pubitemid 350182388)
14. th percentile cut-off independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction. Clin Chem. 2005;51:2198-200. (Pubitemid 41532650)
15. Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation. 2006;113:1958-65.
16. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. NEJM. 2009;361:868-77.
17. Biener M, Mueller M, Vafaie M, et al. Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in a unselected emergency department population. Int J Cardiol. 2012. doi: 10.1016/j.ijcard.2012.09.122.
18. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation. 2003;108:2543-9. (Pubitemid 37451755)
19. Morrow DA, Cannon CP, Jesse RL, et al. National academy of clinical biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem. 2007;53:552-74. (Pubitemid 46580223)
20. Giannitsis E, Becker M, Kurz K, et al. High sensitivity cardiac troponin T for early prediction of evolving non-ST-elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. Clin Chem. 2010;56:642-50.
21. Mueller MJ, Blener M, Vafale M, et al. Absolute and relative kinetic changes of high-sensitivity cardiac troponin T in acute coronary syndrome and in patients with increased troponin in the absence of acute coronary syndrome. Clin Chem. 2012;58:209-18.
22. Apple FS, Pearce LA, Smith SW, Kaczmarek JM, Murakami MAM. Role of monitoring changes in sensitive cardiac troponin I assay results for early diagnosis of myocardial infarction and prediction of risk of adverse events. Clin Chem. 2009;55:930-7.
23. • Reichlin T, Irfan A, Twerenbold R, et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation. 2011;124:136-45. One of the earliest demonstrations of the superiority of following absolute changes in cTn concentration over relative changes for the early detection of AMI.
24. MacRae AR, Kavsak PA, Lustig V, et al. Assessing the requirement for for the 6-hour interval between specimens in the American Heart Association classification of myocardial infarction in epidemiology and clinical research studies. Clin Chem. 2006;52:812-8. (Pubitemid 43673258)
25. Haaf P, Drexler B, Reichlin T, et al. High-sensitivity cardiac troponin in the distinction of acute myocardial infarction from acute cardiac noncoronary artery disease. Circulation. 2012;126:31-40.
26. • Reiter M, Twerenbold R, Reichlin T, et al. Early diagnosis of acute myocardial infarction in patients with pre-existing coronary artery disease using more sensitive cardiac troponin assays. Eur Heart J. 2012;33:988-97. A substudy of the APACE population showing the utility of cTn in detecting AMI in patients with underlying CAD. Depending on the brand of high-sensitive cTn assay used, slightly different cut-off values defining an abnormal cTn level were derived for patients with, versus without CAD, although considerable overlap was noted. Nevertheless, high-sensitive cTn assays performed better than conventional assays in diagnosing AMI early, thereby retaining their prognostic value regardless of the presence of CAD.
27. Gassenmaier T, Buchner S, Birner C, et al. High-sensitive troponin I in acute cardiac conditions: implications of baseline and sequential measurements for diagnosis of myocardial infarction. Atherosclerosis. 2012;222:116-22.
28. Khan NA, Hemmelgarn BR, Tonelli M, Thompson CR, Levin A. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation. 2005;112:3088-96. (Pubitemid 43113440)
29. • Newby LK, Jesse RL, Babb JD, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. JACC. 2012;60:2427-63. An excellent document summarizing data on the appropriate use of cardiac troponin testing in cardiac conditions, including answers to frequently asked questions regarding cardiac troponin, its role in the diagnosis of AMI, and its interpretation.
30. Alyanakian M-A, Dehoux M, Chatel D, et al. Cardiac troponin I in diagnosis of perioperative myocardial infarction after cardiac surgery. J Cardiothorac Vasc Anesth. 1998;12:288-94. (Pubitemid 28280362)
31. Soraas CL, Friis C, Engebretsen KVT, et al. Troponin T is a better predictor than creatine kinase-MB of long-term mortality after coronary artery bypass graft surgery. Am Heart J. 2012;164:779-85.
32. Buse GAL, Koller MT, Grapow M, et al. 12-Month outcome after cardiac surgery: prediction by troponin T in combination with the European system for cardiac operative risk evaluation. Ann Thorac Surg. 2009;88:1806-13.
33. Domanski MJ, Mahaffey K, Hasselblad V, et al. Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA. 2011;305:585-91.
34. Buse GAL, Koller MT, Grapow M, et al. The prognostic value of troponin release after adult cardiac surgery - a meta analysis. European J Cardio-thoracic Surg. 2010;37:399-406.
35. • Daaman P, Wallentin L, Fox KAA, et al. Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 trials. Circulation. 2012;125:568-76. A study analyzing data on peri-procedural MI events from three well known large, prospective, randomized trials primarily enrolling high risk patients with CAD. This was mostly a study of peri-PCI AMI as the number of patients undergoing CABG was only 21 as compared to 176 undergoing PCI. The analysis confirms earlier data suggesting no significant impact on CV mortality related to the occurrence of peri-PCI MI.
36. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. JACC. 1998;31:241-51. (Pubitemid 28153440)
37. Zimarino M, Affinito V. The prognosis of periprocedural myocardial infarction after percutaneous coronary interventions. Cardiovasc Revasc Med. 2013;14:32-6.
38. Kini AS, Lee P, Marmur JD, et al. Correlation of postpercutaneous coronary intervention creatinine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol. 2004;93:18-23. (Pubitemid 38022028)
39. Novack V, Pencina M, Cohen DJ, Kleiman NS, Yen C-H, et al. Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med. 2012;172:502-8.
40. Vranckx P, Farooq V, Garg S, et al. Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: impact on outcome reporting. Heart. 2012;98:1424-30.
41. Nageh T, Sherwood RA, Harris BM, Thomas MR. Prognotic role of cardiac troponin I after percutaneous coronary intervention in stable coronary disease. Heart. 2005;91:1181-5. (Pubitemid 41192395)
42. Mohammed AA, Januzzi Jr JL. Clinical applications of highly sensitive troponin assays. Cardiol Rev. 2010;18:12-9.
43. De Antonio M, Lupon J, Galan A, Vila J, Urrutia A, Bayes-Genis A. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. Am Heart J. 2012;163:821-8.
44. Martinez-Rumayor AA, De Lemos JA, Rohatgi AK, et al. Addition of highly sensitive troponin T and N-terminal pro-B-type natriuretic peptide to electrocardiography for detection of left ventricular hypertrophy: results from the Dallas Heart Study. Hypertension. 2013;61:105-11.
45. Neeland IJ, Drazner MH, Berry JD, et al. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population. JACC. 2013;61:187-95.
46. Imazio M, Demichelis B, Cecchi E, et al. Cardiac troponin I in acute pericarditis. JACC. 2003;42:2144-8. (Pubitemid 37549900)
47. Chalela JA, Ezzeddine MA, Davis L, Warach S. Myocardial injury in acute stroke - a troponin I study. Neurocrit Care. 2004;3:343-6. (Pubitemid 41278349)
48. Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ. 2005;173:1191-202. (Pubitemid 41637819)
49. • Agewall S, Giannitsis E, Jernberg T, Katus H. Troponin elevation in coronary vs noncoronary disease. Eur Heart J. 2011;32:404-11. Excellent review on the occurrence of myocardial necrosis in non-ischemic cardiac conditions.
50. Garg R, Singh A, Khaja A, Martin A, Aggarwal K. How does volume status affect BNP and troponin levels as markers of cardiovascular status in peritoneal dialysis? Congest Heart Fail. 2009;15:240-4.
51. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13:699-709. (Pubitemid 34567375)
52. Yoon GJ, Telli ML, Kao DP, et al. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies. Are clinicians responding optimally? JACC. 2010;56:1644-50.
53. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749-54. (Pubitemid 38737923)
54. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107:1375-80.
55. Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M. Biochemical markers for prediction of chemotherapy induced cardiotoxicity. Systematic review of the literature and recommendations for use. Am J Pathol. 2008;130:688-95.
56. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474-81. (Pubitemid 44901520)
57. •• Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. JACC. 2010;55:213-20. An important study building on previous work by this group and others emphasizing the importance of monitoring cardiotoxicity in response to chemotherapy using cTn as an early marker of myocardial injury to guide medical decisions regarding early medical interventions to prevent or treat LV dysfunction.
58. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta analysis. Circulation. 2007;116:427-33. (Pubitemid 47196548)
59. Jimenez D, Uresandi F, Otero R, et al. Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and metaanalysis. Chest. 2009;136:974-82.
60. Walter T, Aphaltrer P, Weilbacher F, et al. Predictive value of high-sensitivity troponin I and D-dimer assays for adverse outcome in patients with acute pulmonary embolism. Exp Ther Med. 2013;5:5860590.
61. Ferrari E, Moceri P, Crouzet C, Doyen D, Cerboni P. Timing of troponin I measurement in pulmonary embolism. Heart. 2012;98:732-5.
62. Lankeit M, Jimenez D, Kostrubiec M, Dellas C, Hasenfuss G, et al. Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation. 2011;124:2716-24.
63. Jung SK, Kim WY, Sohn CH, Kang HD, Oh SH, et al. Value of cardiac troponin I for predicting in-hospital occurrence of hypotension in stable patients with acute pulmonary embolism. Shock. 2013;39:50-4.